-
-
-
-
-
-
-
Form S-1/A Inhibikase Therapeutics,
-
-
-
-
-
-
-
Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones
-
-
-
-
-
-
-
Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy
-
-
-
-
-
-
-
Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock
-
-
-
-
-
-
-
Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering
-
-
-
-
66,407 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

